"Safety and Efficacy of Covishield Vaccine"
Author(s): Rhythm Verma and Guddi Laishram*
Abstract
Corona virus disease epidemic brought in not only morbidity and mortality but farther unknown challenges such as public health, food availability, human interactions, and economy across the world. It opened new gates of difficulties to be faced by the entire world which were hard to imagine by anyone. It questioned the existence of entire humankind globally. The accessibility and conveyance of an efficacious and safe vaccine to civilisation in the world is a prospective possibility to overcome these fears and challenges. Nations need to use their assets and make the accessibility of antibodies widespread without which the effect of the immunisation drive will not be figured it out. Despite India’s considerable population and its requisites, it's looked upon with deep trust to deliver at this pivotal time in the human civilisation. India is more than willing to do its part and is expanding its reach.
Free immunisation for corona virus disease started on 16th of January 2021 in India and Government of India is motivating all its inhabitants to participate in probably the world's largest vaccine campaign. Four out of the eight COVID-19 vaccines in India are in various stages of testing were introduced. Covishield (name given to Oxford Astra-Zeneca Vaccine in India) and Covaxin, a local vaccine developed by Bharat Biotech, has been authorised by India's pharmaceuticals authorities for restricted emergency use. Indian manufacturers said that they would be able to handle the country's future pandemic vaccination requirements. Prior to the pandemic, there was enough staff and cold chain infrastructure in place to vaccine thirty lakh healthcare professionals. The Government of India took brisk efforts to improve the manufacturing capacity of vaccine by the country, as well as to construct an effective online infrastructure for treating and preventing disease epidemics.